Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
European Physician Survey of EGFR Inhibitor Prescribing Patterns
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: Physician Survey
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 453
- Registration Number
- NCT01652833
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Anemia in Chronic Kidney Disease Patients Not on Dialysis
- Interventions
- Biological: Darbepoetin alfaOther: Placebo
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 756
- Registration Number
- NCT01652872
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice
Completed
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Biological: Denosumab
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT01652690
- Locations
- 🇨🇿
Osteocentrum Zlin, Zlin, Czechia
🇸🇰Research Site, Zilina, Slovakia
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
Phase 2
Completed
- Conditions
- Hypercholesterolemia and High Risk for Cardiovascular Events
- Interventions
- Other: PlaceboBiological: Evolocumab
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 310
- Registration Number
- NCT01652703
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT01634178
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT01634191
- Locations
- 🇺🇸
PRA International, Lenexa, Kansas, United States
🇺🇸Clinical Development Services, Dallas, Texas, United States
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Phase 2
Completed
- Conditions
- Severe Familial Hypercholesterolemia
- Interventions
- Biological: Evolocumab
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT01624142
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Transition From Alendronate to Romosozumab (AMG 785)
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT01588509
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Phase 2
Completed
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Biological: EvolocumabDrug: Placebo
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 58
- Registration Number
- NCT01588496
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Ankylosing Spondyloarthritis
- Interventions
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 490
- Registration Number
- NCT01583374
- Locations
- 🇺🇸
Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇨🇦Credit Valley Professional Building, Mississauga, Ontario, Canada
🇨🇿PV-Medical s.r.o., Zlin, Czechia
© Copyright 2025. All Rights Reserved by MedPath